India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition," according to a government statement on Thursday and a document posted on the regulator's website.

Sun and Ranbaxy have been asked by the regulator to publish details of the deal within 10 working days on their websites as well as in four national newspapers. The CCI also sought comments or objections from the public on the proposed deal.

Sun Pharma agreed in April to buy Ranbaxy from Japan's Daiichi Sankyo Ltd to create the world's fifth-largest maker of generic drugs. Both companies have previously said they expect to complete the deal by December.

Related Articles

Other News

As U.S. takes aim at Chinese biotech giants, lawyers warn of ‘dramatic impact’  

by Sarah Wong |

The United States has extended its sprawling trade and technology control regime to cover the biotechnology sector as it is determined to “de-risk” from China.

Features

INDONESIA: Arrested Development

by Nimitt Dixit |

When Indonesia established a carbon trading mechanism last year, the move was welcomed across the board. However, a lack of strong implementing regulations, regulatory uncertainty, and insufficient business incentives have combined to ensure slow-going for the country's carbon trading market.

Features

EXPLAINER: TikTok Set To Restart E-Commerce in Indonesia, but Doubts Persist

by Sarah Wong |

TikTok has been engulfed in regulatory whirlwinds across the world, which have put a dent in its global ambitions. In the United States, the popular social media app owned by ByteDance faces a ban unless its Beijing-based parent company divests its U.S. operations, and in Indonesia, TikTok had to temporarily quit its e-commerce business as its shopping arm ran into a slew of obstacles.